

Contents

Volume I: Defining the Right Antibody Composition

Quick Reference List of Antibodies by International Nonproprietary Name XXIII

Quick Reference List of Antibodies by Brand Name XXV

A Greeting by the Editors XXVII

Foreword to the First Edition XXIX

Foreword to the Second Edition XXXI

List of Contributors XXXIII

Abbreviations LI

Appendix: Marketed Monoclonal Antibodies Compendium LXXXIII

1 Therapeutic Antibodies – from Past to Future 1

Stefan Dübel and Janice M. Reichert

Part I: Selecting and Shaping the Antibody Molecule 15

2 Selection Strategies for Monoclonal Antibodies 17

Gerhard Moldenhauer

3 Antibody Phage Display 43

Michael Hust, André Frenzel, Florian Tomszak, Jonas Kügler, and Stefan Dübel

4 Transgenic Animals Derived by DNA Microinjection 77

Marianne Brüggemann, Michael J. Osborn, Biao Ma, Suzanne Avis, Ignacio Anegón, and Roland Buelow

5 Humanization Strategies 89

José W. Saldanha

6 Antibody Affinity 115

André Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, and Larry Green

- 7 **Fc Engineering** 141
Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner, and Thomas Valerius
- 8 **Glycosylation of Antibody Molecules** 171
Roy Jefferis
- 9 **Bioinformatics Tools for Analysis of Antibodies** 201
Andrew C.R. Martin and James Allen
- 10 **How to Use IMGT® for Therapeutic Antibody Engineering** 229
Marie-Paule Lefranc
- Part II: Modified Antibodies** 265
- 11 **Bispecific Antibodies** 267
Dafne Müller and Roland E. Kontermann
- 12 **Single-Domain Antibodies: An Overview** 311
Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, and Bruce Hamilton
- 13 **Antibody–Drug Conjugates: New Frontier in Cancer Therapeutics** 341
Rajeeva Singh, John M. Lambert, and Ravi V. J. Chari
- 14 **Antibody-Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins** 363
Athanasios Mavratzas, Michaela A.E. Arndt, Stefan Kiesgen, and Jürgen Krauss
- Part III: Emerging Technologies** 391
- 15 **Emerging Technologies for Antibody Selection** 393
Mingyue He and Michael J. Taussig
- 16 **Anti-Idiotypic Antibodies** 407
Alejandro López-Requena, Oscar R. Burrone, and Rolando Pérez
- 17 **Non-Antibody Scaffolds as Alternative Therapeutic Agents** 435
Markus Fiedler and Arne Skerra
- 18 **Antibody-Directed Enzyme Prodrug Therapy (ADEPT)** 475
Surinder K. Sharma, Kerry A. Chester and Kenneth D. Bagshawe

- 19 **Engineered Antibody Domains as Candidate Therapeutics** 487
Weizao Chen, Ponraj Prabakaran, and Dimiter S. Dimitrov

- 20 **Chimeric Antigen Receptors –“CARs”** 519
Ulf Petrausch and Thomas Schirrmann

- 21 **Emerging Alternative Production Systems** 561
Benjamin Sommer, Holger Laux, Andre Frenzel, and Thomas Jostock

Volume II: Clinical Development of Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name XXIII

Quick Reference List of Antibodies by Brand Name XXV

A Greeting by the Editors XXVII

Foreword to the First Edition XXIX

Foreword to the Second Edition XXXI

List of Contributors XXXIII

Abbreviations LI

Appendix: Marketed Monoclonal Antibodies Compendium LXXXIII

Part IV: The Way into the Clinic 601

- 22 **Process Development and Manufacturing of Therapeutic Antibodies** 603
Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser, and Hütto Kaufmann

- 23 **The Immunogenicity of Therapeutic Antibodies** 665
Melody Sauerborn

- 24 **Biosimilar Monoclonal Antibodies** 681
Susanne D. Pippig, Carsten Brockmeyer, and Robert E. Zoubek

- 25 **Patent Issues Relating to Therapeutic Antibodies** 705
Barbara Rigby, Michael Braunagel, and Deborah Owen

Part V: Therapeutic Antibody Pipeline 735

- 26 **Monoclonal Antibody Cancer Treatments in Phase III Clinical Trials** 737
Ulf Petrausch and Peter Markus Deckert

- 27 **Antibodies in Cancer Treatment: Early Clinical Development** 787
Matthew Zibelman, Hossein Borghaei, and Anthony J. Olszanski

- 28 **Targeting Angiogenesis by Therapeutic Antibodies** 823
Onat Kadioglu, Ean Jeong Seo, and Thomas Efferth
- 29 **Antibodies in Phase III Studies for Immunological Disorders** 851
Penelope Ward and Mark Bodmer
- 30 **Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders** 927
Frank R. Brennan
- 31 **MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders** 969
Frank R. Brennan
- 32 **T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** 1079
Frank R. Brennan
- 33 **B-Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** 1115
Frank R. Brennan
- 34 **Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders** 1127
Frank R. Brennan
- 35 **Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** 1145
Frank R. Brennan
- 36 **IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** 1159
Frank R. Brennan
- 37 **Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders** 1165
Frank R. Brennan
- 38 **mAbs Targeting Apoptosis, Angiogenesis Inhibitors, and Other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders** 1175
Frank R. Brennan
- 39 ***In vitro* Studies and Clinical Trials about Monoclonal Antibodies Used in Infectiology** 1195
Guillaume Desoubieux

- 40 Immunotherapeutics for Neurological Disorders 1215**
Anne Messer, Kevin Manley, and Cynthia A. Lemere

Part VI: Gaining Marketing Approval 1231

- 41 Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy 1233**
Marjorie A. Shapiro, Patrick G. Swann, and M. Stacey Ricci

- 42 Regulatory Review: Clinical to Market Transition 1263**
Gabriele Dallmann

- 43 Monoclonal Antibody Nomenclature for Clinical Studies (USA) 1283**
Stephanie C. Shubat

Volume III: Approved Therapeutic Antibodies

Quick Reference List of Antibodies by International Nonproprietary Name XXIII

Quick Reference List of Antibodies by Brand Name XXV

A Greeting by the Editors XXVII

Foreword to the First Edition XXIX

Foreword to the Second Edition XXXI

List of Contributors XXXIII

Abbreviations LI

Appendix: Marketed Monoclonal Antibodies Compendium LXXXIII

Part VII: Approved Therapeutic Antibodies 1289

- 44 Oligoclonal and Polyclonal Antibody Preparations 1291**
Rishab K. Gupta and Mark C. Glassy

- 45 Adalimumab (Humira®) 1309**
Janice M. Reichert

- 46 Alemtuzumab (Lemtrada, MabCampath) 1323**
Thomas Elter, Michael Hallek, and Janice M. Reichert

- 47 Basiliximab (Simulect®) and Daclizumab (Zenapax®) 1375**
Nadim Mahmud, Burcin Taner, and Nasimul Ahsan

- 48 Belimumab (Benlysta®) 1405**
Pamela M. K Lutalo, Natasha Jordan, Thi-Sau Migone, and David P. D'Cruz

- 49 **Brentuximab Vedotin (Adcetris®) for the Treatment of CD30-Positive Hematologic Malignancies** 1417
Niels W.C.J. van de Donk and Eugen Dhimolea

- 50 **Canakinumab (ILARIS®)** 1445
Hermann Gram

- 51 **Catumaxomab (Removab) –Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination** 1463
Horst Lindhofer, Michael Stanglmaier, Raymund Buhmann, Michael Jäger, Daniel Klunker, Peter Ruf, and Juergen Hess

- 52 **Cetuximab (Erbix®)** 1501
Sonja Wilke and Michael Hust

- 53 **Denosumab (Prolia®)** 1521
Torsten Meyer

- 54 **Efalizumab (Raptiva)** 1531
Karlheinz Schmitt-Rau

- 55 **Calicheamicin Conjugates: Gemtuzumab Ozogamicin (Mylotarg), Inotuzumab Ozogamicin** 1545
Matthias Peipp and Martin Gramatzki

- 56 **Golimumab (Simponi®)** 1565
Sohini Mazumdar and Janice M. Reichert

- 57 **Yttrium-90 Ibritumomab Tiuxetan (Zevalin®)** 1579
Karin Hohloch, Björn Chapuy, and Lorenz Trümper

- 58 **Infliximab (Remicade®)** 1599
Christian Antoni and Maria Wiekowski

- 59 **Ipilimumab (Yervoy®)** 1619
Teresa Alonso Gordo, Javier Puente Vázquez, and Eduardo Díaz-Rubio

- 60 **Muromonab-CD3 (Orthoclone OKT®3)** 1645
Harald Becker and Janice M. Reichert

- 61 **Nimotuzumab: A Humanized Anti-EGFR Antibody** 1679
Tania Crombet Ramos

- 62 **Obinutuzumab (Gazyva®), a Novel Glycoengineered Type II CD20 Antibody for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma** 1695
Christian Klein, Marina Bacac, Pablo Umaña, and Michael Wenger

Volume IV: Approved Therapeutic Antibodies and *in vivo* Diagnostics

Quick Reference List of Antibodies by International Nonproprietary Name XXIII

Quick Reference List of Antibodies by Brand Name XXV

A Greeting by the Editors XXVII

Foreword to the First Edition XXIX

Foreword to the Second Edition XXXI

List of Contributors XXXIII

Abbreviations LI

Appendix: Marketed Monoclonal Antibodies Compendium LXXXIII

- 63 Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity 1733**
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren, and Ronald P. Taylor
- 63.1 Introduction and Preliminary Comments 1733
- 63.2 Physical and Immunochemical Characteristics of OFA Compared to RTX 1735
- 63.2.1 Interactions with CD20 1735
- 63.2.2 Development and Characterization of OFA 1737
- 63.2.3 Epitope Characterization 1737
- 63.2.4 *In vitro* Investigations Demonstrate That OFA Is Far More Effective Than RTX in Promoting CDC of Cell Lines and of CLL Cells 1739
- 63.3 Functional Characterizations 1743
- 63.3.1 Dose Requirements for Sustained *In vivo* Activity of OFA in Preclinical Models 1743
- 63.3.2 Clearance from the Circulation via the Mononuclear Phagocytic System (MPS) 1744
- 63.3.3 On the Role of Neutrophils 1745
- 63.3.4 C3b Deposition and Complement Receptors 1745
- 63.3.5 Complement as a Confounding Factor 1745
- 63.3.6 Mouse Models 1746
- 63.3.7 No Apoptosis 1748
- 63.4 CD20: It Is certainly a Good Target, but How Well Characterized Is It? 1748
- 63.4.1 CD20 Is not Shed into the Bloodstream 1748
- 63.4.2 CD20 on B Cells Can Be “Shaved,” Especially When Effector Functions Are Exhausted 1749
- 63.4.3 After OFA or RTX Binding, CD20 Can Indeed Be Internalized, but Slowly 1752
- 63.5 Key Results of Clinical Trials with OFA 1752
- 63.5.1 Introduction 1752
- 63.5.2 OFA Monotherapy for CLL: Phase 1/2 1753
- 63.5.3 OFA Monotherapy for FL: a Dose-Ranging Study 1753

63.5.4	OFA Monotherapy: the Pivotal Trial for CLL	1756
63.5.5	Combination with Chemotherapy: OFA plus FC for CLL	1757
63.5.6	Combination with Chemotherapy: O-CHOP for FL	1758
63.5.7	Combination with Chemotherapy: OFA plus Lenalidomide or Ibrutinib for CLL	1758
63.5.8	OFA Monotherapy: RTX-Refractory FL	1759
63.5.9	Rheumatoid Arthritis	1760
63.6	Summary and Future Directions	1761
	Abbreviations	1762
63.7	Disclosures	1762
	References	1763
64	Omalizumab (Xolair) – Anti-Immunoglobulin E Treatment in Allergic Diseases	1775
	<i>Claus Kroegel and Martin Foerster</i>	
64.1	Introduction	1775
64.2	The Biology of the IgE Molecule	1778
64.2.1	IgE Distribution and Blood Concentration	1779
64.2.2	IgE Synthesis and Regulation	1779
64.3	IgE Receptors	1780
64.3.1	FcεRI (High-Affinity IgE Receptor)	1781
64.3.1.1	FcεRI–IgE Binding	1781
64.3.1.2	FcεRI Activation	1782
64.3.1.3	Regulation of FcεRI Expression	1783
64.3.2	FcεRII (Low-Affinity IgE Receptor, CD23)	1783
64.3.2.1	FcεRII–IgE Binding	1784
64.3.2.2	FcεRII Activation	1784
64.3.2.3	FcεRII/CD23 Functions	1784
64.4	Cell Distribution of IgE	1785
64.4.1	Effector Cell-Associated IgE	1785
64.4.2	Antigen-Presenting Cell-Associated IgE	1786
64.5	Physiologic and Pathophysiologic Significance of IgE	1786
64.6	The Concept of Anti-IgE-Based Treatment	1787
64.7	Construction of the Monoclonal Anti-IgE Molecule	1787
64.7.1	Antibody Generation	1787
64.7.2	Complex Formation and Tissue Distribution	1788
64.7.3	Interactions with IgE	1792
64.8	Efficacy	1792
64.8.1	Preclinical Results	1792
64.8.2	Clinical Studies	1793
64.9	Anti-Inflammatory Effects of Omalizumab	1797
64.9.1	Effects on Serum Free IgE Levels	1797
64.9.2	Effect on Cytokines	1799
64.9.3	Effects on FcεRI Cell Expression	1799
64.9.4	Effect on Dendritic Cell APCs	1800

64.9.5	Effect on Eosinophils	1800
64.9.6	Effects on B Cells	1801
64.10	Pharmacological Properties of Omalizumab	1802
64.10.1	Pharmacodynamics	1802
64.10.2	Pharmacokinetics	1802
64.11	Adverse Effects	1802
64.11.1	Systemic Side Effects	1803
64.11.2	Local Reactions	1803
64.11.3	Serious Adverse Effects	1803
64.11.4	Immune Complex Diseases	1804
64.11.5	Long-Term Adverse Effects	1804
64.12	Indications	1804
64.13	Contraindications	1804
64.14	Preparation for Use	1805
64.15	Administration	1806
64.16	Dosing of Omalizumab	1806
64.17	Response to Treatment	1808
64.17.1	Onset of Action of Anti-Immunoglobulin E Effect	1808
64.17.2	Duration of Treatment	1808
64.18	Assessment of Therapeutic Response	1809
64.19	Monitoring of Therapy	1810
64.20	Drug Interactions	1810
64.21	Pregnancy and Lactation	1810
64.22	Cost	1811
64.23	Non-approved Diseases	1811
64.23.1	Allergic Rhinitis	1811
64.23.2	Urticaria/Angioedema	1812
64.23.3	Insect Venom Allergy and Specific Immunotherapy	1813
64.23.4	Mast Cell Activation Syndrome (MCAS)	1814
64.24	Conclusions	1814
	Acknowledgments	1815
	References	1815
	Websites	1824
65	Palivizumab (Synagis®)	1825
	<i>Louis Bont</i>	
65.1	Nature, Role in Disease, and Biology of the Target	1825
65.1.1	Respiratory Syncytial Virus (RSV)-Induced Disease and RSV Epidemiology	1825
65.1.2	Target of the Antibody: the RSV Virion	1826
65.1.3	Correlates of Protection from Disease	1827
65.2	Origin, Engineering, and Humanization of the Antibody	1829
65.3	Mechanism of Action and Preclinical Results	1831
65.4	Production, Downstream Processing, and Galenics of the Antibody	1833

65.5	Summary of Results from Clinical Studies	1835
65.5.1	Phase 3 Trials	1835
65.5.1.1	Palivizumab in Premature Infants	1836
65.5.1.2	Palivizumab in Children with Significant Congenital Heart Disease (CHD)	1838
65.6	Indications and Usage	1839
65.7	Clinical Reports after Approval	1840
65.8	Protective Efficacy as a Function of Palivizumab Serum Concentration?	1842
65.9	Postmarketing Experience with Regard to Adverse Events (AEs)	1843
65.10	Toward Improved Versions of Palivizumab	1845
65.11	Summary	1845
	Acknowledgments	1846
	Abbreviations	1846
	References	1847
66	Panitumumab (Vectibix®): A Treatment for Metastatic Colorectal Cancer	1855
	<i>Jonas Kügler</i>	
66.1	Introduction	1855
66.1.1	Colorectal Cancer	1855
66.1.2	Epidermal Growth Factor	1855
66.2	Panitumumab (Vectibix)	1856
66.2.1	Panitumumab (Vectibix) Development	1856
66.2.2	Preclinical Results of Panitumumab (Vectibix)	1857
66.2.3	Resistance to Panitumumab (Vectibix)	1857
66.2.4	Approval	1858
66.2.5	Production, Galenics, and Pharmacokinetic Properties of Panitumumab	1858
66.3	Results from Clinical Studies	1859
66.3.1	Phase I Clinical Studies: Safety, Pharmacokinetics, and Activity	1859
66.3.2	Monotherapy of Panitumumab for mCRC	1859
66.3.3	First-Line Combination Therapy of Panitumumab for mCRC	1862
66.3.4	Second-Line Combination Therapy of Panitumumab for mCRC	1862
66.3.5	Antibody Combination Therapy	1863
66.3.6	Panitumumab in Head and Neck Cancer	1864
66.4	Summary and Outlook	1865
	References	1865
67	Pertuzumab (Perjeta®)	1871
	<i>Jose Angel García-Saénz, Fernando Moreno Anton, and Coralía Bueno Muiño</i>	
67.1	HER2-Positive Breast Cancer	1871
67.2	Mechanisms of Trastuzumab Resistance	1871
67.2.1	Loss of Trastuzumab Binding	1871

67.2.2	Activation of Downstream Signaling Pathways	1872
67.2.3	Overexpression of Alternative ErbB Ligands and Dimerization of Receptors	1873
67.2.4	Interaction of HER2 with Other Structurally Unrelated Receptors	1873
67.3	Preclinical Development	1874
67.4	Pertuzumab Clinical Development	1875
67.5	Pertuzumab Cardiac Safety Profile	1879
	References	1880

68 Ranibizumab (Lucentis): a New Anti-Angiogenic Treatment in Ophthalmology

Nicolas Leveziel, Marc Ohresser, and Gilles Paintaud

68.1	Introduction	1883
68.1.1	Age-Related Macular Degeneration	1884
68.1.2	Diabetic Macular Edema	1886
68.1.3	Branch and Central Retinal Vein Occlusion	1886
68.1.4	Myopic Choroidal Neovascularization	1886
68.2	Ranibizumab: Clinical Studies in Retinal Disorders	1887
68.2.1	Exudative AMD	1887
68.2.2	Clinical Studies in Diabetic Macular Edema	1889
68.2.3	Clinical Studies in Retinal Vein Occlusion	1890
68.2.4	Clinical Studies in Myopic Choroidal Neovascularization	1891
68.3	Other Molecules with Anti-VEGF Effect of Clinical Use in Retinal Disorders	1891
68.3.1	Bevacizumab	1892
68.3.2	Aflibercept	1893
	References	1894

69 Raxibacumab, Human Monoclonal Antibody against Anthrax Toxin

Sally D. Bolmer and Thi-Sau Migone

69.1	Introduction	1899
69.2	Development of Raxibacumab	1900
69.2.1	Anthrax Toxins	1900
69.2.2	Molecule Generation and <i>In vitro</i> Pharmacology	1901
69.2.2.1	Generation of Raxibacumab	1901
69.2.2.2	Raxibacumab Mechanism of Action	1901
69.3	Demonstration of Effectiveness under the Animal Rule	1901
69.3.1	Animal Models	1902
69.3.2	Monotherapy Studies	1903
69.3.3	Antibiotic Combination Studies	1904
69.4	Safety	1905
69.4.1	Nonclinical Safety	1905
69.4.2	Human Safety	1905

69.5	Dosing	1906
69.6	Indication	1906
69.7	Conclusion	1907
	Abbreviations	1907
	References	1907
70	Rituximab (Rituxan®)	1909
	<i>Axel Böhnke and Michael Wenger</i>	
70.1	Introduction	1909
70.1.1	Production, Design, and Structure of Rituximab	1909
70.1.2	CD20 as a Therapeutic Target	1910
70.1.3	Mode of Action	1911
70.1.4	Preclinical Studies	1913
70.1.5	Pharmacokinetic Studies	1913
70.2	Rituximab Clinical Data in B-Cell Lymphoma	1914
70.2.1	Overview of B-Cell Lymphoma	1914
70.2.1.1	Overview of Indolent and Aggressive B-Cell Lymphoma	1914
70.2.1.2	Overview of CLL	1916
70.2.2	Rituximab plus Chemotherapy Induction Therapy in Indolent B-Cell Lymphoma	1917
70.2.2.1	Rituximab plus Chemotherapy in Previously Untreated Indolent B-Cell Lymphoma	1922
70.2.2.2	Rituximab plus Chemotherapy in Relapsed/Refractory Indolent B-Cell Lymphoma	1927
70.2.2.3	Meta-Analysis of Rituximab and Chemotherapy in Indolent B-Cell Lymphoma	1930
70.2.3	Induction Therapy with Rituximab plus Immune Modulators in Indolent B-Cell Lymphoma	1931
70.2.3.1	Rituximab Plus Immune System Modulators in Previously Untreated Indolent B-Cell Lymphoma	1931
70.2.3.2	Rituximab plus Immune Modulators in Relapsed/Refractory Indolent B-Cell Lymphoma	1932
70.2.4	Induction with Rituximab Monotherapy in Indolent B-Cell Lymphoma	1933
70.2.4.1	Rituximab Monotherapy in Previously Untreated Indolent B-Cell Lymphoma	1933
70.2.4.2	Rituximab Monotherapy in Relapsed Indolent B-Cell Lymphoma	1934
70.2.5	Rituximab in Other Subtypes of Indolent Lymphoma	1935
70.2.5.1	Rituximab in Marginal Zone Lymphoma	1935
70.2.5.2	Rituximab in Small Lymphocytic Lymphoma	1936
70.2.5.3	Rituximab in Waldenström's Macroglobulinemia	1936
70.2.6	Rituximab Maintenance Therapy in Indolent Lymphoma	1937
70.2.6.1	Rituximab Maintenance Therapy Following Monotherapy Induction	1937

- 70.2.6.2 Rituximab Maintenance Therapy Following Chemotherapy Induction 1941
- 70.2.6.3 Rituximab Maintenance Therapy Following Rituximab Chemotherapy Induction 1942
- 70.2.7 Rituximab in Aggressive B-Cell Lymphoma 1944
- 70.2.7.1 Phase II Studies of Rituximab plus Chemotherapy in Previously Untreated Aggressive B-Cell Lymphoma 1945
- 70.2.7.2 Phase III Studies and Population Analysis of Rituximab plus Chemotherapy in Previously Untreated DLBCL 1950
- 70.2.7.3 Phase III Studies of Rituximab plus Dose-Densified Chemotherapy in Previously Untreated Aggressive B-Cell Lymphoma 1954
- 70.2.7.4 Rituximab plus Chemotherapy in Relapsed Aggressive B-Cell Lymphoma 1955
- 70.2.7.5 Rituximab Monotherapy in Aggressive B-Cell Lymphoma 1956
- 70.2.7.6 Rituximab in Other Subtypes of Aggressive B-Cell Lymphoma 1957
- 70.2.8 Rituximab in MCL 1959
- 70.2.8.1 Rituximab plus Chemotherapy in Previously Untreated MCL 1959
- 70.2.8.2 Rituximab plus Chemotherapy in Relapsed MCL 1963
- 70.2.8.3 Rituximab Monotherapy in MCL 1963
- 70.2.8.4 Rituximab in Combination with Immune Modulators in Relapsed MCL 1963
- 70.2.9 Rituximab in CLL 1964
- 70.2.9.1 Rituximab Monotherapy in CLL 1964
- 70.2.9.2 Rituximab plus Chemotherapy in Previously Untreated CLL 1964
- 70.2.9.3 Rituximab plus Chemotherapy in Relapsed CLL 1970
- 70.2.9.4 Rituximab in Combination with Non-CHEMO Agents in CLL 1971
- 70.2.10 Rituximab Retreatment in B-Cell Lymphoma and CLL 1973
- 70.2.11 Rituximab in the Transplant Setting 1974
- 70.2.12 Rituximab in Other Malignancies of B-Cell Origin 1976
- 70.2.12.1 Rituximab in Post-Transplant Lymphoproliferative Disorder 1976
- 70.2.12.2 Rituximab in HIV-Associated Lymphoma 1977
- 70.2.12.3 Rituximab in Primary CNS Lymphoma 1978
- 70.2.12.4 Rituximab in Hairy Cell Leukemia 1978
- 70.2.12.5 Rituximab in Hodgkin's Disease 1979
- 70.3 Rituximab in Autoimmune Disorders 1979
- 70.3.1 Rituximab in Rheumatoid Arthritis (RA) 1980
- 70.3.2 Rituximab in Systemic Lupus Erythematosus (SLE) 1982
- 70.3.3 Rituximab in Autoimmune Cytopenias and Hemophilia 1982
- 70.3.4 Rituximab in Chronic Graft-versus-Host Disease 1983
- 70.3.5 Rituximab in ANCA-Associated Vasculitis 1983
- 70.3.6 Rituximab in Other Autoimmune Disorders 1984
- 70.4 Development of a Subcutaneous Rituximab Formulation (Rituximab SC) in B-Cell Lymphoma and CLL 1985
- 70.4.1 Background and Rationale to Develop Rituximab SC 1985

70.4.2	Clinical Studies with Rituximab SC	1986
70.4.2.1	Clinical Studies with Rituximab SC in Follicular Lymphoma Maintenance (SparkThera (BP22333))	1986
70.4.2.2	Clinical Studies with Rituximab SC in Follicular Lymphoma Induction Followed by Maintenance (SABRINA (BO22334))	1992
70.4.2.3	Clinical Studies with Rituximab SC in CLL (SAWYER (BO25341))	1992
70.4.3	Summary and Conclusion: Rituximab SC	1993
70.5	Summary and Conclusions	1994
	References	1996
	Websites	2021
71	Tocilizumab (Actemra®)	2023
	<i>Graeme Jones and Changhai Ding</i>	
71.1	Introduction	2023
71.2	Biological Activities and Signaling of IL-6	2023
71.3	Targeting IL-6 with Monoclonal Antibodies	2024
71.4	Targeting IL-6 in Rheumatoid Arthritis	2025
71.4.1	Monotherapy Trials	2025
71.4.2	Monotherapy Long-Term Extensions	2028
71.4.3	Combined Therapy with Methotrexate or Other DMARDs	2028
71.4.4	Effect on Radiographic Progression	2030
71.5	Targeting IL-6 in Systemic-Onset Juvenile Idiopathic Arthritis	2030
71.6	Targeting IL-6 in Castleman's Disease	2032
71.7	Other Indications	2032
71.8	Adverse Events Associated with Targeting the IL-6 Receptor	2033
71.8.1	Infections	2033
71.8.2	Liver Function Abnormalities	2034
71.8.3	Hyperlipidemia	2035
71.8.4	Immunogenic Potential	2036
71.9	Current State of Play	2036
	References	2036
72	Trastuzumab (Herceptin®) and Ado-Trastuzumab Emtansine (Kadcyla®): Treatments for HER2-Positive Breast Cancer	2041
	<i>Ruhe Chowdhury and Paul Ellis</i>	
72.1	Introduction	2041
72.2	Metastatic Breast Cancer	2043
72.2.1	Trastuzumab Monotherapy	2043
72.2.2	Trastuzumab in Combination with Taxanes	2044
72.2.3	Trastuzumab in Combination with Other Standard Chemotherapy	2046
72.2.4	Trastuzumab in Triple Combination	2047
72.2.5	Trastuzumab in Combination with Hormonal Therapies	2047

72.2.6	Trastuzumab in Combination with Monoclonal Antibodies	2048
72.2.7	Trastuzumab in Combination with Tyrosine Kinase Inhibitors	2048
72.3	Early Breast Cancer	2048
72.3.1	Duration of Adjuvant Treatment	2053
72.3.2	Trastuzumab Treatment in Other Tumor Types	2053
72.3.3	Safety	2053
72.4	Cardiac Adverse Events	2054
72.5	Infusion-Related Reactions	2057
72.6	Age Considerations	2058
72.7	Patient Considerations	2058
72.8	Dosing/Scheduling	2059
72.9	Ado-Trastuzumab Emtansine (T-DM1), Trade Name Kadcyla	2059
72.10	Safety and Side Effects	2061
72.11	FDA Approval	2062
72.12	Conclusions	2062
	References	2062
73	Ustekinumab (Stelara®)	2069
	<i>Oya Cingoz, Stefan Dübel, and Janice M. Reichert</i>	
73.1	Introduction	2069
73.2	Psoriasis	2071
73.2.1	Preclinical Data	2071
73.2.2	Clinical Studies	2072
73.2.2.1	PHOENIX-1 (NCT00267969)	2072
73.2.2.2	PHOENIX-2 (NCT00307437)	2073
73.2.2.3	ACCEPT (NCT00454584)	2073
73.2.3	Other Studies	2074
73.3	Psoriatic Arthritis	2074
73.4	Crohn's Disease	2076
73.4.1	CERTIFI (NCT00771667)	2077
73.5	Multiple Sclerosis	2077
73.6	Meta Analyses on Long-Term Use	2078
73.7	Ongoing Studies, New Indications, and Outlook	2083
	References	2083
74	Abciximab (Reopro®), Bevacizumab (Avastin®), Certolizumab Pegol (Cimzia®), Eculizumab (Soliris®), Natalizumab (Tysabri®)	2087
	<i>Janice M. Reichert</i>	
74.1	Abciximab (Reopro)	2087
74.1.1	Pivotal Studies in Approved Indications	2088
74.2	Bevacizumab (Avastin)	2089

74.2.1	Safety	2090
74.2.2	Pivotal Studies in Breast Cancer	2091
74.2.3	Pivotal Studies in Ovarian Cancer	2092
74.2.4	Pivotal Studies in Glioblastoma	2094
74.2.5	Investigational Studies in Cervical Cancer	2095
74.3	Certolizumab Pegol (Cimzia)	2095
74.3.1	Safety	2096
74.3.2	Pivotal Studies in Crohn's Disease	2097
74.3.3	Pivotal Studies in Rheumatoid Arthritis	2098
74.3.4	Pivotal Studies Investigational Indications	2100
74.4	Eculizumab (Soliris)	2101
74.4.1	Pivotal Studies in Approved Indications	2102
74.4.2	Investigation Use of Eculizumab	2103
74.5	Natalizumab (Tysabri)	2104
74.5.1	Safety	2105
74.5.2	Pivotal Studies in Approved Indications	2105
	References	2107
75	Itolizumab (Alzumab®), Mogamulizumab (Poteligeo®), and Tositumomab (Bexxar®)	2113
	<i>Stefan Dübel</i>	
75.1	Itolizumab (Alzumab)	2113
75.1.1	Clinical Studies	2114
75.2	Mogamulizumab (Poteligeo)	2115
75.2.1	Clinical Studies	2115
75.3	Tositumomab; Iodine ¹³¹ I Tositumomab (Bexxar)	2116
75.3.1	Clinical Studies	2117
75.3.2	Therapeutic Regimen	2117
	References	2118
	Further Reading	2120
	Information Sources	2120
	Part VIII: In vivo Diagnostics	2121
76	Radiolabeled Antibodies for Diagnostic Imaging	2123
	<i>Christopher J. Palestro</i>	
76.1	Introduction	2123
76.2	Oncology	2123
76.2.1	Satumomab (OncoScint®)	2123
76.2.2	Arcitumomab (CEA-Scan™)	2124
76.2.3	¹¹¹ In-Capromab (ProstaScint™)	2126
76.3	Cardiology	2129
76.3.1	¹¹¹ In-Imicromab (MyoScint™)	2129
76.4	Infection	2130
76.4.1	Besilesomab (Scintimun®)	2131

76.4.2	Fanolesomab (LeuTech [®] , NeutroSpec [®])	2132
76.4.3	Sulesomab (Leukoscan [®])	2134
76.5	Summary	2137
	References	2138

Index	2143
--------------	------